Chronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham

Transcription

1 Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham

2 Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure of optimal medical management? 3. Comorbidities may provide novel therapeutic targets

3 67 year old Caucasian man under review in CKD clinic

4 vascular bed inflammation normal evolving disease established disease Eardley et al; Kidney International

5 1 million nephrons/kidney unique vasculature Oxygenation po po po

6 High intraglomerular pressure promotes proteinuria and accelerated renal injury Glomerular pressure P GC Proteinuria AT II Inflammation Fibrosis

7 Chronic Kidney Disease (CKD) staging GFR stage ml/min GFR term G1 90 normal or high G normal or mild G3a mild to moderate G3b moderate to severe G severe G5 <15 kidney failure Albuminuria UACR mg/mmol Albuminuria A1 <3 normal A high (micro) A3 >30 very high (macro)

8 An ACR of 100 mg/mmol = AER of 1g/d Normal High (micro) Very High (macro) ACR (mg/mmol) < >30 PCR (mg/mmol) < >50 AER (mg/day) < >300 PER (mg/day < >500 Urine diptest -ve to trace Trace to 1+ >1+

9 Risk of end-stage renal failure (ESRF) in respect of egfr and proteinuria ACR 30+ mg/mmol ACR 3-29 mg/mmol ACR < 3mg/mmol Adapted from Levey et al KI 2011

10 70 year female; egfr 20 ml/min, ACR 0.5 mg/mmol Risk of end-stage renal failure at 2-years? % 2. 7% 3. 17% 4. 37%

11 11

12

13 40 year male; egfr 20 ml/min, ACR 100 mg/mmol Risk of end-stage renal failure at 2-years? % 2. 7% 3. 17% 4. 37%

14

15 Relative risk of death by stage of CKD (female) ACR <3 mg/mmol ACR >30 mg/mmol egfr CKD 3a CKD 3b CKD 4 CKD 5 15 based on Nitsch BMJ 346 (2013): doi: /bmj.f324.

16 Change in LV mass (g) following nephrectomy humans 12 months after living kidney donation Moody et al: Hypertension. 2016;67:

17 Evidence base for CKD Therapy Patient group Comment ACEi/ARB Diabetes & ACR>3 Include normotensive ACEi/ARB ACR >30 (no diabetes) Target BP <130/80 Antihypertensive conventional CKD ACR<30 Target BP <140/90 Statin (for CVD primary prevention) CKD 3-5 Not dialysis Recent phase 3 studies in CKD Target Comment Combined RAAS blockade NCT RAAS Study terminated Bardoxolone NCT Fibrosis Study terminated Immunosuppression (IgA nephropathy) NCT Anaemia NCT Inflammation Cardiovascular disease -ve and possible harm Increased risk of stroke with target Hb >120 g/l

18 Three paradigms for chronic disease 1. Acute and chronic disease is closely linked

19 CKD - Slow Progressor Jan-14 Jul-14 Jan-15 Jul-15 Jan-16

20 Proteinuric CKD (fast progressor) Jan-14 Jul-14 Jan-15 Jul-15 Jan-16

21 Acute Kidney Injury on CKD Jan-14 Jul-14 Jan-15 Jul-15 Jan-16

22 Kidney International 2012;Vol 2: Acute Kidney Injury (AKI) Staging Stage Creatinine from baseline Urine output μmol/l or 1.5 2x <0.5 ml/kg/h for 6h times <0.5 ml/kg/h for 12h 3 3 times or 352 μmol/l or on dialysis <0.3 ml/kg/h for 24h or anuria for 12h Only one criterion is required

23 Prognosis of AKI % 33% 16.3% 3.2% No AKI AKI 1 AKI 2 AKI 3 Adapted from Selby NM. et al. Clin J Am Soc Nephrol. 2012;7:

24 AKI (STOP) the major risk factor is CKD Sepsis/Ischaemia 1. Prerenal Toxins ATN 3. Obstruction Parenchymal (RPGN; AIN) 2. Intrinsic

25 25

26

27 Stop ACEi and ARBs in AKI; avoid NSAIDS P GC NSAIDS ACE/ATII inhibitors RAS Dehydration Sepsis Pump failure

28 Three paradigms for chronic disease 1. Acute and chronic disease are intimately linked 2. Stratify risk and tailor interventions around failure of optimal medical management

29 CKD and no ACEi benefit? ACEi commenced Jan-14 Jul-14 Jan-15 Jul-15 Jan-16

30

31 Elevated serum mast-cell tryptase concentration predicts progression to ESRF in patients receiving treatment with an ACEi/ARB. Jesky et al; EJCI 2016

32 Can we use biomarkers in chronic disease to: pathotype for and by treatment response?? identify new targets for intervention?? Jesky et al; EJCI 2016

33 CKD and no ACEi benefit? Jan-14 Jul-14 Jan-15 Jul-15 Jan-16

34 Change in GFR after stopping ACEi Ahmed AK et al NDT 2009: 25; 3977

35 Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease CI: Prof Sunil Bhandari Consultant Nephrologist Honorary Clinical Professor

36 3 years follow-up 2 years recruitment CKD patients stage 4-5 ACEi/ARB treatments Eligible for STOP-ACEi study? Yes No Excluded Not Meeting Criteria Declined Other Reason Randomise 1:1 ratio, N=410 Control Arm: Continue ACEi/ARB N=205 Experimental Arm: Discontinue ACEi/ARB N=205 3 Year Follow-Up 3-monthly visits - routine tests (egfr, FBC, BCP, urinary PCR), BP, documentation of ESA dose, adverse events, compliance and changes in medication Extra tests at annual visits - QOL questionnaire, weight and BMI, 6-minute walk test, ECG, and bloods for C-reactive protein, cystatin-c, NT-proBNP, ACE/renin levels and biomarkers TARGET BP <140/85

37 Three paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure of optimal medical management 3. Comorbidities may provide novel therapeutic targets.

38 Risk of death based on comorbidities: 31,245 primary care based patients with kidney function testing and comorbidities assigned Number of co-morbidities Jesky et al; BMJ Open 2013

39 What is the commonest chronic disease? 1. Periodontitis 2. Type 2 diabetes 3. Chronic kidney disease 4. Obesity 5. Coronary artery disease 6. Peripheral vascular disease

40 Periodontitis

41 Severe Periodontitis 11% of adults 39% of adults with high risk CKD Sharma et al J Clin Periodontol (2014) 41:7, 653-6

42 NHANES III ( ) Diabetes, periodontal status and mortality in patients with CKD Mean follow-up time 8 years (1 month-18 years) Cox PH regression analysis

43

44

45

46

47

48 Patient Reported Outcomes (PROs)? A PRO is any report of the status of a patient s health condition that comes directly from the patient, without interpretation of the patient s response by a clinician or anyone else. FDA guidance: Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009

49 PROs in Routine Practice Smartphone Tablet PC Phone Voice-Recognition Scanned Paper-Copy KDQOL-36 General Health (SF-12) Quality of Life CKD Symptoms

50 eprom SYSTEM - University Hospital Birmingham Patient receives automated message of reassurance for scores within normal limits Alert Monitoring Example screenshot from Danish Ambuflex system Patient and renal team alerted to closely monitor worsening symptoms and to take action if concerned Member of renal team contacts patient to determine need to escalate care Longitudinal eprom Data in Clinic Facilitates patient-centred care and shared decision making

51 Summary 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure of optimal medical management 3. Comorbidities may provide novel therapeutic targets